Reaction profile

The FDA adverse-event record for respiratory tract neoplasm nos

27 FDA reports name respiratory tract neoplasm nos, a lower-volume reaction in the CVM extract (VeDDRA 888). Plate stamps and neighbourhood peers follow.

#2048 of 2,481
by report volume (all reactions)
27
reports citing this reaction
55.6%
death-coded share
Dog
most-affected species
Verify with FDA CVM →

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Respiratory tract neoplasm NOS has 27 reports now versus 25 in that prior snapshot: 2 more (8.0%).

Report change
+2
Death-coded reports
+1
Death-coded share
−0.4 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Respiratory tract neoplasm NOS changes

FDA AER · VeDDRA plate

Code 888 VOL-TRACE

VOL-TRACE · DEATH-HOT · LOWER-Q · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL

  • VOL-TRACE 27 reports
  • DEATH-HOT 55.6%
  • LOWER-Q #2048/2481
  • PHOTO-FINISH Abortion spontaneous
  • SPECIES-DOG Dog · 23
  • DRUG-LEAD Spinosad · 4
  • DESK-WIDE 17 breeds
  • BOOK-FULL 8/8 fields

Nearest volume peer: Abortion spontaneous (±0 reports)

Upper-third death-coded share drives the outcome stamps on this plate; volume band, corpus rank, and co-report peers follow. Not a clinical diagnosis.

Lower-volume neighbourhood around Respiratory tract neoplasm NOS

Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.

Vomiting · highest174348Abortion spontaneous · near27Aplastic anaemia · near27Cyanotic spots/blotch… · near27Cyst rupture NOS · near27Respiratory tract neo… · thi…27Urinary tract neoplas… · low…10
FDA AER report volume · neighbourhood around Respiratory tract neoplasm NOS

Respiratory tract neoplasm NOS: high death-coded share in the FDA AER plate

Signature read: Respiratory tract neoplasm NOS's 55.6% death-coded share is among the highest in the openFDA reaction corpus. Report volume is lower-third scale: 27 named reports in the openFDA extract. Death-coded share is upper-third: 15 of 27 reports (55.6% of named reports). Nearest volume peer: Abortion spontaneous (±0 reports). Lead species Dog (23). Lead co-reported drug Spinosad (4).

Read these counts as reporting volume, not risk: per our methodology, A high death-coded share in FDA filings does not prove causation; co-reporting is voluntary temporal association only. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Dog 23
Cat 4

Breeds Most Affected

Domestic Shorthair 4
Schnauzer - Miniature 2
Retriever - Labrador 2
Beagle 2
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 2
Saint Bernard Dog 2
Dog (unknown) 2
Spaniel - King Charles Cavalier 2
Chow Chow 1
Shepherd Dog - German 1

Associated Drugs

Spinosad 4
Oclacitinib Maleate 4
Afoxolaner 4
Gabapentin 4
Carprofen 3
Trilostane 3
Milbemycin Oxime + Spinosad 3
Cefovecin 2
Propofol 2
Isoflurane 2
Meloxicam 2
Hydromorphone Hcl 2
Diazepam 2
Grapiprant 2
Ivermectin 2
Polysulfated Glycosaminoglycan 2
Ursodiol 2
Ivermectin + Pyrantel As Pamoate Salt 2
Pimobendan 2
Fentanyl 1

What to do with this reaction

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Respiratory tract neoplasm NOS (#2048 of 2,481 by report volume); death-coded 55.6%. PlainBreed reaction plate · death-coded share stamp 55.6% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →